What Is KPV Peptide? Sequence, Origin and Research Applications

Sep 29, 2026 Leave a message

KPV Peptide 

Field Detail
Full name L-Lysyl-L-prolyl-L-valine (Lys-Pro-Val)
Sequence Lys-Pro-Val; exact terminal form confirmed on batch COA
CAS number 67727-97-3 for the specified free-acid form; verify against the exact molecular form and batch documentation
Molecular formula C₁₆H₃₀N₄O₄ (free-acid form)
Molecular weight 342.43 g/mol (free-acid form)
Peptide length 3 amino acids (tripeptide)
α-MSH relationship C-terminal fragment, α-MSH(11–13)
Product form Lyophilized powder (typical); solution or custom formats depend on supplier
Intended use Laboratory research; cosmetic or other applications require target-market regulatory verification

 

What Do the Letters K, P and V Mean?

KPV is a single-letter abbreviation for the three-amino-acid sequence:

  • K = Lysine - a basic amino acid with a four-carbon side chain terminating in an amino group. In KPV, lysine contributes a positive charge at physiological pH and is the N-terminal residue.
  • P = Proline - a cyclic amino acid whose side chain bonds back to the peptide backbone, introducing conformational rigidity. Proline sits in the middle of KPV and constrains the peptide's three-dimensional shape.
  • V = Valine - a branched-chain aliphatic amino acid. In KPV, valine is the C-terminal residue and contributes hydrophobic character to the tripeptide.

The order is fixed. KPV means Lys-Pro-Val specifically. VKP (Val-Lys-Pro) or KVP (Lys-Val-Pro) are different peptides with different physicochemical properties and should not be treated as equivalent to KPV.

 

How Is KPV Related to α-MSH?

α-MSH is a 13-amino-acid endogenous melanocortin peptide with the sequence Ac-SYSMEHFRWGKPV-NH₂. It participates in melanocortin signaling through melanocortin receptors in multiple tissues. KPV corresponds to the final three amino-acid residues, positions 11–13, often written as α-MSH(11–13).

Two distinctions matter for buyers and researchers:

Fragment versus full peptide. KPV is a three-amino-acid fragment of α-MSH, not the full 13-amino-acid molecule. Biological effects reported for full-length α-MSH cannot automatically be assigned to KPV.

Terminal and counter-ion form. KPV refers to the Lys-Pro-Val sequence, but commercial material may be supplied in different terminal or counter-ion forms depending on the product specification. Buyers should confirm the exact molecular form, molecular weight and analytical identity on the batch-specific documentation.

 

How Is KPV Peptide Manufactured?

KPV is typically produced by solid-phase peptide synthesis (SPPS), the standard method for short synthetic peptides. The C-terminal residue is attached to a solid support, followed by iterative cycles of N-terminal deprotection and amino-acid coupling to assemble the sequence. After synthesis, the peptide is cleaved from the resin with removal of protecting groups, purified as required, lyophilized and analytically verified. The general process includes:

  • Resin loading / attachment of the C-terminal residue
  • Iterative deprotection and amino-acid coupling
  • Final cleavage and protecting-group removal
  • Purification, commonly by preparative RP-HPLC
  • Lyophilization
  • Analytical identity and purity verification (HPLC and LC-MS)

Specific equipment, yields, coupling reagents, cleavage conditions and purification parameters are manufacturer- and batch-specific. Without HDM's confirmed production documentation, this page describes the general synthetic route only and does not state proprietary process details.

 

What Is KPV Studied For?

Published KPV research spans several experimental directions:

  • Inflammatory-signaling research - KPV has been studied in cell and animal models of inflammation, including work examining its relationship to the broader α-MSH melanocortin pathway.
  • Epithelial-cell models - studies have used epithelial and intestinal cell lines to examine KPV uptake and signaling responses.
  • Keratinocyte stress - a 2025 study examined KPV in PM10-exposed human HaCaT keratinocytes and a 3D skin model, reporting associations with reduced ROS, modulated MAPK/NF-κB signaling and lower inflammatory markers.
  • Intestinal peptide transport - KPV has been shown to be taken up by the intestinal peptide transporter PepT1 in experimental models, a route relevant to oral peptide delivery research.
  • Oxidative-stress models - KPV has been evaluated in cell models involving reactive oxygen species and oxidative damage pathways.
  • Peptide-delivery systems - because KPV is a short tripeptide, it has been used as a model substrate for studying peptide transport, stability and formulation approaches.

These are research directions, not established clinical applications. Most published data come from cell-based and animal models.

 

What Does the Evidence Actually Support?

Evidence Type What It Can Show What It Cannot Show
In vitro Cell-level pathways and biomarker changes Human therapeutic efficacy
Animal model Responses under defined experimental conditions Human safety, efficacy or dosing
Human research Outcomes under a defined clinical design Conclusions beyond the studied population, dose and endpoints
Marketing claim Product positioning or intended-use language Scientific efficacy or safety by itself

The current evidence base supports further laboratory investigation of KPV in inflammatory, oxidative-stress and epithelial-cell models. It does not establish clinical efficacy, optimal human dosing, or long-term safety. Each evidence level answers a different question: in vitro studies establish whether a pathway can be modulated under controlled cell conditions; animal studies establish whether an effect can be observed in a living organism under defined dosing; human research establishes whether an effect is reproducible in people with appropriate statistical power. Marketing claims, by contrast, describe product positioning and are not a substitute for any of the above. This tiered approach helps buyers distinguish between mechanistic research interest and established clinical utility.

 

Is KPV a Cosmetic Ingredient or Research Peptide?

KPV is primarily discussed and supplied as a research peptide. Before positioning KPV as a cosmetic active ingredient, buyers should verify the ingredient's current regulatory and inventory status in the specific target market, including any applicable ingredient-naming, safety-assessment and product-notification requirements. This distinguishes KPV from well-established cosmetic peptides such as Acetyl Hexapeptide-8 or Palmitoyl Pentapeptide-4, which have recognized INCI names and are commonly listed in cosmetic ingredient databases.

HDM's KPV content is therefore framed around laboratory research use and raw-material identity, not around finished-product cosmetic claims.

 

FAQ

What is the full name of KPV?

KPV is L-Lysyl-L-prolyl-L-valine, a tripeptide with the sequence Lys-Pro-Val.

What is the amino-acid sequence of KPV?

The sequence is Lys-Pro-Val. The exact terminal form and molecular weight should be confirmed on the batch-specific documentation.

Is KPV the same as α-MSH?

No. KPV corresponds to positions 11–13 (the C-terminal tripeptide) of α-MSH, but it is a fragment and should not be treated as functionally equivalent to the full 13-amino-acid peptide.

Is KPV naturally occurring or synthetic?

The KPV sequence occurs naturally as the C-terminal fragment of α-MSH, but commercial KPV raw material is typically produced by solid-phase peptide synthesis and supplied as a synthetic research peptide.

Is KPV approved for human use?

No. KPV is a research peptide; published evidence is dominated by cell and animal models, and no human clinical indication is established. Any human use requires appropriate regulatory and medical oversight.

Looking for KPV peptide powder for laboratory research? HDM Biotech provides batch-specific COA, analytical documentation, sample support and bulk supply options according to the confirmed product specification.

Contact:
Whatsapp & Mobile: +86 19991242181

Email:sales@hdmbio.com

 

References

  1. Sung J, Ju S-Y, Park S, Jung W-K, Je J-Y, Lee S-J. Lysine-Proline-Valine peptide mitigates fine dust-induced keratinocyte apoptosis and inflammation by regulating oxidative stress and modulating the MAPK/NF-κB pathway. Tissue & Cell. 2025;95:102837. DOI: 10.1016/j.tice.2025.102837. PMID: 40073467.
  2. Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631–637. PMID: 12750433.
  3. Elliott RJ, Szabo M, Wagner MJ, Kemp EH, MacNeil S, Haycock JW. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. Journal of Investigative Dermatology. 2004;122(4):1010–1019. PMID: 15102092.
  4. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PMID: 18061177.
  5. PubChem. Lys-Pro-Val (CID 125672). Molecular formula C₁₆H₃₀N₄O₄; molecular weight 342.43 g/mol. Accessed 2026.

Send Inquiry

whatsapp

Phone

E-mail

Inquiry